You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥-B(02137.HK)擬額外投入1億美元推進針對SARS-CoV-2(導致COVID-19的病毒)的聯合療法BRII-196/BRII-198在全球註冊申請和商業化進程
格隆匯 09-07 19:07

格隆匯9月7日丨騰盛博藥-B(02137.HK)公吿,公司將額外投入1億美元,以推進其在研的針對SARS-CoV-2(導致COVID-19的病毒)的聯合療法BRII-196/BRII-198在全球的註冊申請和商業化進程。

BRII-196/BRII-198是一種SARS-CoV-2中和單克隆抗體聯合療法。最近NIH贊助的ACTIV-2的3期試驗中期結果證明,與安慰劑相比,在非住院並處於臨牀進展的高風險(名義單側p值=0.00001)的COVID-19患者中,該聯合療法在住院和死亡的聯合終點方面的相對風險在統計上大幅降低了78%。在清晰顯示臨牀及安全結果後,獨立數據安全監督理事會允許提前發佈中期結果,同時完整的研究隨訪仍在進行中。

這項研究是在世界各地的臨牀試驗地點進行,包括美國、巴西、南非、墨西哥、阿根廷及菲律賓,並於2021年1月至7月全球新型SARS-CoV-2變異株快速出現期間招募患者。作為研究的一部分,BRII-196/BRII-198聯合療法的臨牀有效性數據亦將按變異株的類型進行評估。目前的體外嵌合病毒實驗數據表明,BRII-196/BRII-198聯合療法對廣受關注的主要SARS-CoV-2變異株均保持中和活性,包括以下常見的病毒變異株:B.1.1.7("阿爾法",lpha)、B.1.351("貝塔",Beta)、P.1("伽馬",Gamma)、B.1.429("伊普西龍",Epsilon)、B.1.617.2("德爾塔",Delta)、C.37("拉姆達",Lambda)以及B.1.621("繆",Mu)。

上述額外投資金額為1億美元,將來自公司首次公開發售前從各投資者募集的資金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account